Search Within

Sarat Chandarlapaty

  1. "Andrew Seidman"
Formats
  1. Meeting Abstract (5)
  2. Journal Article (2)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (7)
  2. Breast Medicine Service (7)
  3. Department of Medicine (7)
  4. GSK Faculty (7)
  5. Human Oncology and Pathogenesis Program (7)
  6. Solid Tumor Oncology Division (7)

More Groups

People
  1. Andrew Seidman (7)
  2. Larry Norton (6)
  3. Shanu Modi (5)
  4. Sujata Patil (4)
  5. Angemael Syldor (3)
  6. Clifford Hudis (3)

More People

Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2016 (1)
  4. 2014 (1)
  5. 2012 (1)
  6. 2011 (2)
Publications
  1. Cancer Research (3)
  2. Journal of Clinical Oncology (2)
  3. npj Breast Cancer (2)
Publishers
  1. American Association for Cancer Research (3)
  2. American Society of Clinical Oncology (2)
  3. Nature Publishing Group (2)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: A matched case analysis
    Journal Article

    Moss, N. S.; Singh, J. M.; Reiner, A. S.; Drago, J. Z.; Modi, S.; Seidman, A. D.; Chandarlapaty, S.; Ross, D. S.
    npj Breast Cancer (2023)

    Fulltext@MSK | Save
  • Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
    Journal Article

    Ferraro, E.; Singh, J.; Patil, S.; Razavi, P.; Modi, S.; Chandarlapaty, S.; Barrio, A. V.; Malani, R.; Mellinghoff, I. K.; Boire, A.; more...
    npj Breast Cancer (2022)

    Fulltext@MSK | Save
  • Optimization of intermittent high dose lapatinib administration with or without capecitabine: A rational approach to drug dosing and scheduling using Norton-Simon modeling
    Meeting Abstract

    Morikawa, A.; De Stanchina, E.; Patil, S.; Chandarlapaty, S.; Li, B. T.; Norton, L.; Seidman, A. D.
    Cancer Research (2016)

    Fulltext@MSK | Save
  • A virtual consult service to optimize clinical trial participation in patients with metastatic breast cancer
    Meeting Abstract

    Cadoo, K. A.; Shah, P. D.; Charen, A. S.; Bromberg, J.; Comen, E. A.; D'Andrea, G.; Dang, C. T.; Gilewski, T.; Gucalp, A.; Lake, D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+ metastatic breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Modi, S.; Drullinsky, P.; Syldor, A.; Patil, S.; Seidman, A.; Norton, L.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer
    Meeting Abstract

    Gajria, D.; King, T. A.; Pannu, H.; Sakr, R.; Seidman, A. D.; Syldor, A.; Patil, S.; Maybody, M.; Norton, L.; Rosen, N.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Seidman, A. D.; Modi, S.; Dickler, M.; Drullinsky, P.; Syldor, A.; Sujata, P.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save